Novel Androgen Receptor Inhibitors in Non-Metastatic, Castration-Resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis

Yelin Mulati\textsuperscript{1,2,3}, Yu Fan\textsuperscript{1,2,3}, Wei Yu\textsuperscript{1,2,3}, Qian Zhang\textsuperscript{1,2,3,4} and Zhisong He\textsuperscript{1,2,3}

\textsuperscript{1} Department of Urology, Peking University First Hospital, Beijing, China, \textsuperscript{2} Institute of Urology, Peking University, Beijing, China, \textsuperscript{3} National Urological Cancer Center, Beijing, China, \textsuperscript{4} Peking University Binhai Hospital, Tianjin, China

Introduction: Enzalutamide, apalutamide, and darolutamide have all been approved by Food and Drug Administration to treat high-risk non-metastatic castration-resistant prostate cancer (nmCRPC) since 2018 based on interim results of several phase III clinical trials. Final analyses of long-term overall survival (OS) and adverse events (AEs) results of these trials have been successively published recently. To help clinical practice to precisely select optimal treatment for high-risk nmCRPC patients, we performed a network meta-analysis to indirectly compare the final long-term results among these medications.

Methods: PubMed, EMBASE, and Cochrane Libraries were searched for phase III clinical trial that reports OS and AEs results in nmCRPC patients published before January 30, 2021. Primary outcome was OS; secondary outcomes were Time to first chemotherapy, Subsequent antineoplastic therapy rate, and AEs. Firstly, class-level effect was assessed as the second-generation androgen receptor antagonists (SGARAs) were regarded as one whole class compared with placebo through traditional meta-analysis by using Revman 5.4, then a Bayesian network meta-analysis was conducted to give indirect comparison among SGARAs by using R 3.5.3 software. Subgroup analysis of OS was only conducted in the certain subgroups which were available in all included studies.

Results: Three eligible studies including 4,104 participants were finally selected. OS was significantly improved by the SGARAs as a class compared with placebo (HR, 0.74; 95\% CI, 0.66–0.84). Darolutamide had the highest likelihood of providing best OS (p-score=0.802). SGARAs also significantly delayed the first time to chemotherapy (HR, 0.58; 95\% CI, 0.50–0.66). Patients who received darolutamide experienced similar toxicity compared with placebo regarding AEs of grade 3 or higher (OR, 1.3; 95\% CI, 1.0–1.7) and serious AEs (OR, 1.3; 95\% CI, 0.99–1.6). When compared with darolutamide, enzalutamide caused significantly higher toxicity in terms of any AEs (OR, 2.3; 95\% CI,1.5–3.7) and AEs of grade 3 or higher (OR, 1.6; 95\% CI, 1.1–2.2), apalutamide caused significantly more AEs of grade 3 or higher (OR, 1.9; 95\% CI, 1.4–2.7) and serious AEs...
(OR, 1.9; 95% CI, 1.3–2.8). Subgroup analysis showed that SGARAs as a group significantly improved OS in ECOG=1 population, although insignificant results were found in these patients from included studies.

**Conclusions:** SGARAs combined with ADT significantly improved OS when compared with ADT alone in high-risk nmCRPC patients. Darolutamide may not only provide best OS but also have the most favorable safety profile among the included SGARAs in high-risk nmCRPC patients.

**Keywords:** non-metastatic castration-resistant prostate cancer (nmCRPC), hormonal therapies, overall survival (OS), adverse events, network meta-analysis

**INTRODUCTION**

Non-metastatic castration-resistant prostate cancer (nmCRPC) is defined as prostate-specific antigen (PSA) progression and no evidence of distant metastases on conventional imaging in patients at castration levels of serum testosterone (1, 2). Observation plus continuous androgen-deprivation therapy (ADT) used to be the standard of care for all the nmCRPC patients (3, 4). Since 2018, second-generation androgen receptor antagonists (SGARAs), which include enzalutamide, apalutamide, and darolutamide, have all been successively approved by Food and Drug Administration (FDA) to treat high-risk nmCRPC (PSA doubling time <10 months), on the basis of the significant improvement of metastasis-free survival (MFS) in patients with high-risk nmCRPC receiving additional SGAR to ongoing ADT according to interim results of the three clinical phase III trials: PROSPER, SPARTAN, and ARAMIS studies (5–7). However, overall survival (OS) outcomes based on the interim data were immature, and potential benefits of OS provided by SGARAs were not significant. Recently, final analyses of the three trials reporting the long-term OS and adverse events (AEs) results have all been published (8–10). The three studies consistently showed significant improvement of overall survival accompanied with acceptable toxicity in patients who received SGARAs plus ADT compared with patients who received placebo plus ADT. However, the lack of head-to-head comparison of long-term OS and AEs results among the three SGARAs made it difficult to help the clinical practice precisely. As a result, we did a systematic review and meta-analysis to determine the efficacy and safety profile of SGARAs, then indirectly compared the latest long-term results of efficacy and safety among the SGARAs through Bayesian network meta-analysis to find out the optimal treatment for patients with high-risk nmCRPC.

**STUDY SELECTION**

A systematic review was conducted through PubMed, EMBASE, and Cochrane Libraries on January 30, 2021. The searching strategy is specifically presented in Supplement Material 1.

All the references were imported into EndnoteX8 to be screened. Initial screening was conducted by two independent investigators based on title and abstract. Potential relevant studies were send to full-text review. A third author was consulted to resolve any disagreements between the two investigators.

We included phase III randomized clinical trials comparing OS and AE results of nmCRPC patients who received SGAR combining ADT with patients who received placebo plus ADT.

The following conditions were defined as exclusion criteria: (1) non-English studies; (2) absence of overall survival (OS) outcomes; (3) reviews, conference abstracts, protocols, comments.

**DATA EXTRACTION**

A pre-designed Microsoft Excel table was used to extract general information and clinical characteristics from the studies finally included.

The primary outcome was overall survival (OS), and secondary outcomes were Time to first chemotherapy, Subsequent antineoplastic therapy rate, and Adverse events (AEs).

We extracted hazard ratio (HR) and 95% confidence intervals (CI) for primary and secondary endpoints if HR with 95% CI were available, or extracted number of events otherwise. Data extraction was performed by two independent authors. OS was defined as time from randomization to death of any cause. Time to first chemotherapy was defined as time from randomization to the first use of cytotoxic chemotherapy for prostate cancer. Subsequent antineoplastic therapy rate was defined as percentage of patients who received other new antineoplastic drugs. Adverse events (AEs) were defined and categorized according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

**STATISTICAL ANALYSIS**

Traditional meta-analysis of included studies was conducted initially to give an overall impression of SGARAs as one class compared with placebo. In this part, analyses were conducted using Review Manager5.3. Inverse variance technique was
chased for meta-analysis of HRs for efficacy outcomes, while the Mantel-Haenszel method was used for meta-analysis of binary variable data (e.g., AEs). Random effect model was applied in all analysis above. The risk of bias was assessed according to the Cochrane Collaboration’s tool for each included studies (13). Heterogeneity was assessed using I² statistics during meta-analysis. I² values greater than 25, 50, or 75% indicate low, moderate, or high heterogeneity, respectively. Secondly, we performed Bayesian network meta-analysis to compare the efficacy and safety of available SGARAs using Gemtc package in R 3.5.3 software.

Estimated differences in logHR and standard error were calculated based on published HRs and its 95% confidence intervals (CIs) to analyze efficacy outcomes (14). HR and 95% credible interval (Crl) were displayed as relative treatment effects. Estimated odds ratios (ORs) and 95% Crl were calculated for analysis of AEs using dichotomous data. Ranking probability and surface under the cumulative ranking curves (SUCRA) were synthesized to estimate the relative ranking of efficacy and safety of the candidate treatments. Random or fixed effect model was used where appropriate. Subgroup analysis of OS was conducted only in certain subgroups that were available in all the included studies.

RESULTS
A total of 927 publications were identified from initial database searching. Supplementary Figure 1 shows the PRISMA flowchart of study selection procedure. After duplications removal, title and abstract screening, and full-text reviewing, three eligible studies including 4,104 participants were selected for final analysis (8–10). Baseline characteristics of the three included studies are summarized in Table 1. The three trials used enzalutamide+ADT, apalutamide+ADT, and darolutamide+ADT as intervention therapy, respectively.

There was no difference of ranking results between the fixed effect model and random effect models with the former demonstrating a better fit in NMA. Risk of bias and quality assessment of included studies are shown in Supplementary Figure 2.

Overall Survival
OS was significantly improved by SGARAs as one class compared with placebo in meta-analysis (HR, 0.74; 95% CI, 0.66–0.84), I² = 0% (see Figure 1). All the three agents significantly improved OS, respectively. There was no significant difference in OS among the SGARAs according to NMA. However, based on NMA results of OS ranking (see Figure 2 and Supplementary Figures 3, 4), darolutamide had the highest likelihood of providing the best OS (p-score=0.802), followed by enzalutamide and apalutamide (p-score=0.682 and 0.512, respectively).

Subsequent Antineoplastic Therapy Rate
The use of subsequent antineoplastic therapy was significantly reduced by SGARAs compared with placebo (OR, 0.24; 95% CI, 0.14–0.42), I² = 94% (see Figure 1). In NMA (see Supplementary Figures 5, 6), significantly more patients in enzalutamide group and apalutamide group used subsequent antineoplastic therapy compared with darolutamide group (OR, 1.9, 2.7; 95% CI, 1.4–2.7, 1.9–3.8, respectively).

Time to First Use of Chemotherapy
SGARAs significantly delayed the time to first use of chemotherapy compared with placebo (HR, 0.58; 95% CI, 0.50–0.66), I² = 0% (see Figure 1). No significant difference was found among SGARAs regarding the time to first use of chemotherapy in NMA.

Adverse Events
AEs were assessed through multiple endpoints, included any AEs, AEs of grade 3 or higher, and serious AEs (SAE). SGARAs as a class were associated with significantly higher toxicity no matter which endpoint was assessed (see Figure 1). Darolutamide experienced similar toxicity compared with placebo according to AEs of grade 3 or higher (OR, 1.3; 95% CI, 1.0–1.7), SAEs (OR, 1.3; 95% CI, 0.99–1.6) (see Figure 2). Enzalutamide and apalutamide caused significantly higher toxicity than darolutamide according to AEs of grade 3 or higher (OR, 1.6, 1.9; 95% CI, 1.1–2.2, 1.4–2.7). Enzalutamide was associated with significantly higher toxicity than darolutamide according to any AEs (OR, 2.3; 95% CI, 1.5–3.7).

TABLE 1 | Baseline characteristics of included studies.

| Characteristics | ARAMIS (2020) | PROSPER (2020) | SPARTAN (2020) |
|-----------------|--------------|----------------|----------------|
| Treatments      | Darolutamide+ADT | Placebo+ADT | Enzalutamid+ADT | Placebo+ADT | Apalutamide+ADT | Placebo+ADT |
| Median age, y (range) | 74 (48–95) | 74 (50–92) | 74 (50–96) | 73 (53–92) | 74 (48–94) | 74 (52–97) |
| Median PSA ng/ml (range) | 9.0 (3.3–183.3) | 9.7 (1.5–885.2) | 11.1 (3.8–1071.1) | 10.2 (3.6–247.8) | 7.78 | 7.96 |
| Median PSADT, months | 4.4 | 4.7 | 3.8 | 3.6 | 4.4 | 4.5 |
| LN metastasis | YES | 163 (17) | 158 (29) | NR | 133 (16.5) | 65 (16.2) |
| | NO | 792 (83) | 296 (71) | NR | 673 (83.3) | 336 (83.8) |
| ECOG | 0 | 650 (68) | 391 (71) | 747 (80) | 382 (82) | 623 (77) | 311 (78) |
| | 1 | 305 (32) | 163 (29) | 185 (20) | 85 (18) | 183 (23) | 89 (22) |
| Bone target therapy | Yes | 31 (3) | 32 (6) | 105 (11) | 48 (10) | 82 (10) | 39 (10) |
| | No | 924 (97) | 522 (94) | 828 (89) | 420 (90) | 724 (90) | 362 (90) |

Data presented as median (range) or n(%). PSA, prostate specific antigen; PSADT, PSA doubling time; LN, lymph node; NR, not reported; ECOG, Eastern Cooperative Oncology Group.
### FIGURE 1

**A** Meta-analysis results of included studies. (A) Overall survival. (B) Time to first chemotherapy. (C) The use of subsequent antineoplastic therapy. (D) Any adverse events. (E) Adverse events of grade 3 or higher. (F) Serious adverse events.

#### A: Overall survival

| Study or Subgroup | log[Hazard Ratio] | SE | Weight | Hazard Ratio IV, Random, 95% CI | Hazard Ratio IV, Random, 95% CI |
|-------------------|------------------|----|--------|---------------------------------|---------------------------------|
| Fizazi 2020       | -0.371           | 0.129 | 22.9% | 0.69 [0.54, 0.89]               |                                |
| Smith 2020        | -0.248           | 0.096 | 41.3% | 0.78 [0.65, 0.94]               |                                |
| Sterberg 2020     | -0.315           | 0.103 | 35.9% | 0.73 [0.60, 0.89]               |                                |
| **Total (95% CI)** | **100.0%**       |     |        | **0.74 [0.66, 0.84]**           | **0.74 [0.66, 0.84]**           |
| Heterogeneity: Tau² = 0.00; Chi² = 0.62, df = 2 (P = 0.73); I² = 0% |
| Test for overall effect: Z = 4.87 (P < 0.00001) |

#### B: Time to first chemotherapy

| Study or Subgroup | log[Hazard Ratio] | SE | Weight | Hazard Ratio IV, Random, 95% CI | Hazard Ratio IV, Random, 95% CI |
|-------------------|------------------|----|--------|---------------------------------|---------------------------------|
| Fizazi 2020       | -0.545           | 0.139 | 25.9% | 0.58 [0.44, 0.76]               |                                |
| Smith 2020        | -0.462           | 0.128 | 30.5% | 0.63 [0.49, 0.81]               |                                |
| Sterberg 2020     | -0.616           | 0.107 | 43.6% | 0.54 [0.44, 0.67]               |                                |
| **Total (95% CI)** | **100.0%**       |     |        | **0.58 [0.50, 0.66]**           | **0.58 [0.50, 0.66]**           |
| Heterogeneity: Tau² = 0.00; Chi² = 0.85, df = 2 (P = 0.65); I² = 0% |
| Test for overall effect: Z = 7.79 (P < 0.00001) |

#### C: The use of subsequent antineoplastic therapy

| Study or Subgroup | Experimental Events Total | Control Events Total | Weight | Odds Ratio M-H, Random, 95% CI | Odds Ratio M-H, Random, 95% CI |
|-------------------|---------------------------|----------------------|--------|---------------------------------|---------------------------------|
| Fizazi 2020       | 141                       | 955                  | 33.3% | 0.14 [0.11, 0.18]               |                                |
| Smith 2020        | 781                       | 806                  | 33.1% | 0.37 [0.29, 0.48]               |                                |
| Sterberg 2020     | 310                       | 930                  | 33.5% | 0.27 [0.21, 0.34]               |                                |
| **Total (95% CI)** | **2691**                  | **1420**             | **100.0%** | **0.24 [0.14, 0.42]**           | **0.24 [0.14, 0.42]**           |
| Total events      | 837                       | 895                  |        |                                 |                                 |
| Heterogeneity: Tau² = 0.23; Chi² = 31.25, df = 2 (P < 0.00001); I² = 94% |
| Test for overall effect: Z = 4.99 (P < 0.00001) |

#### D: Any adverse events

| Study or Subgroup | Experimental Events Total | Control Events Total | Weight | Odds Ratio M-H, Random, 95% CI | Odds Ratio M-H, Random, 95% CI |
|-------------------|---------------------------|----------------------|--------|---------------------------------|---------------------------------|
| Fizazi 2020       | 818                       | 954                  | 36.9% | 1.58 [1.20, 2.07]               |                                |
| Smith 2020        | 449                       | 803                  | 28.4% | 2.38 [1.32, 4.28]               |                                |
| Sterberg 2020     | 876                       | 930                  | 34.7% | 3.63 [2.53, 5.21]               |                                |
| **Total (95% CI)** | **2687**                  | **1417**             | **100.0%** | **2.37 [1.33, 4.20]**           | **2.37 [1.33, 4.20]**           |
| Total events      | 2475                      | 1192                 |        |                                 |                                 |
| Heterogeneity: Tau² = 0.21; Chi² = 13.10, df = 2 (P = 0.001); I² = 85% |
| Test for overall effect: Z = 2.95 (P = 0.003) |

#### E: Adverse events of grade 3 or higher

| Study or Subgroup | SGARA Events Total | Placebo Events Total | Weight | Odds Ratio M-H, Random, 95% CI | Odds Ratio M-H, Random, 95% CI |
|-------------------|--------------------|----------------------|--------|---------------------------------|---------------------------------|
| Fizazi 2020       | 251                | 120                  | 33.2% | 1.29 [1.01, 1.66]               |                                |
| Smith 2020        | 449                | 154                  | 33.3% | 2.01 [1.57, 2.57]               |                                |
| Sterberg 2020     | 446                | 126                  | 33.5% | 2.48 [1.95, 3.16]               |                                |
| **Total (95% CI)** | **2687**           | **1417**             | **100.0%** | **1.86 [1.28, 2.71]**           | **1.86 [1.28, 2.71]**           |
| Total events      | 1146               | 400                  |        |                                 |                                 |
| Heterogeneity: Tau² = 0.09; Chi² = 14.11, df = 2 (P = 0.0009); I² = 86% |
| Test for overall effect: Z = 3.24 (P = 0.001) |

#### F: Serious adverse events

| Study or Subgroup | SGARA Events Total | Placebo Events Total | Weight | Odds Ratio M-H, Random, 95% CI | Odds Ratio M-H, Random, 95% CI |
|-------------------|--------------------|----------------------|--------|---------------------------------|---------------------------------|
| Fizazi 2020       | 290                | 99                   | 32.9% | 1.71 [1.30, 2.23]               |                                |
| Smith 2020        | 372                | 100                  | 33.4% | 2.43 [1.88, 3.15]               |                                |
| Sterberg 2020     | 372                | 930                  | 32.9% | 1.74 [1.19, 2.54]               |                                |
| **Total (95% CI)** | **2687**           | **1417**             | **100.0%** | **1.74 [1.19, 2.54]**           | **1.74 [1.19, 2.54]**           |
| Total events      | 911                | 320                  |        |                                 |                                 |
| Heterogeneity: Tau² = 0.09; Chi² = 12.93, df = 2 (P = 0.002); I² = 85% |
| Test for overall effect: Z = 2.86 (P = 0.004) |
Apalutamide was associated with significantly higher toxicity than darolutamide according to serious AEs (OR, 1.9; 95% CI, 1.3–2.8) (see Figure 3).

Subgroup Analysis
Subgroup analysis was conducted only in certain subgroups that were available in all three studies, including PSA doubling time, baseline osteoplastic-targeting therapy, ECOG performance-status, and region (North America). OS was significantly improved in patients who received SGARAs compared with placebo across all these subgroups, except patients with baseline osteoplastic-targeting therapy and patients in North America. Although the improvement was not significant in each included studies respectively in ECOG 1 patients, it became significantly improving OS when SGARAs were regarded as a class compared with placebo in ECOG 1 patients (HR, 0.80, 95% CI, 0.64–0.99) (see Figure 4). In NMA analysis, OS in patients who received osteoplastic-targeting therapy was significantly inferior in patients who received enzalutamide than patients who received darolutamide (Supplementary Figure 7). In the region of North America, darolutamide improved OS significantly compared with apalutamide and enzalutamide (Supplementary Figure 8).

DISCUSSION
The landscape of treatment for nmCRPC patients has evolved (15). FDA has approved enzalutamide, apalutamide, and darolutamide to treat nmCRPC. To guide clinical practice, several NMA studies have been conducted and demonstrated that apalutamide and enzalutamide may provide better MFS than darolutamide, and apalutamide may have the best MFS based on interim results of the three trials (16–19).

According to our study based on the recently published long-term results of OS and AEs, we found that darolutamide not only showed a potential advantage of OS compared with enzalutamide and apalutamide, but also showed best tolerance in terms of AEs in patients with high-risk nmCRPC. It is necessary to point out that patients with known central nervous system malignancies were excluded in PROSPER and SPARTAN, while they were included in the ARAMIS study.

The advantages of darolutamide may be due to the unique molecular structure distinct from enzalutamide and apalutamide, as it gives darolutamide a higher androgen receptor binding affinity and negligible penetration of blood-brain barrier according to the preclinical study (20, 21). In addition, darolutamide can also block the mutant ARs arising in response to ADT, which conferred resistance to enzalutamide and apalutamide (22).

The three trials allowed patients in the placebo group to cross over to receive open-label treatment drug (SGARA) after unblinding treatment assignments, and all these crossed-over patients were still included into placebo group for final OS analysis. Therefore, the more the patients crossed over from placebo group to treatment group, the less significant the potential improvement for OS of treatment drug would be. The crossed over rates differed among the studies. There were 170 of 544 patients (31%), 76 of 401 patients (19%), 87 of 465 patients (19%) in placebo group that crossed over to receive open-label treatment regimen in ARAMIS, SPARTAN, and PROSPER study, respectively. On the contrary, the more patients received the subsequent life-prolonging therapy, the effect of improving OS of treatment drug was more likely to be underestimated. Significantly more patients in enzalutamide group and apalutamide group received subsequent life-prolonging therapy.
therapy than darolutamide group (OR, 1.9, 2.7; 95% CI, 1.4–2.7, 1.9–3.8). As a result, though darolutamide has had the highest likelihood of providing best OS, we still assumed that the advantage was underestimated. Improving OS of cancer patients is the ultimate goal of antineoplasm drug. Our study, applying the latest long-term OS outcomes, showed darolutamide may provide best OS among the three included SGARAs, which was different from the previous NMA results using early OS data (16–18). Previous NMA also showed significantly better MFS in patients who received apalutamide or enzalutamide compared with patients who received darolutamide. However, we found that different censoring rules for MFS analysis were applied in ARAMIS study compared with SPARTAN and PROSPER studies. In PROSPER and SPARTAN trials, patients who were randomly assigned to the study and later found to have had baseline metastatic disease at central review would be left censored for time-to-event analysis (which happened 16 weeks after randomization) (6). In contrast, ARAMIS trial right censored these patients at the date of randomization (5). This difference brought in heterogeneity and may underestimate the MFS of darolutamide. According to our subgroup analysis, insignificant OS outcome was found in the North American population with SGARAs compared with placebo (HR, 0.66; 95% CI, 0.37–1.17). European and Asian subgroup analysis failed to be performed due to different cutoff levels across the three studies. Comparable efficacy and similar safety outcomes were found between the Japanese subgroup population and globally overall population in both ARAMIS and SPARTAN studies (23, 24). However, significantly more skin rash cases were reported in the Japanese subgroup population compared with the overall population in the SPARTAN study (56 vs 23.8%) (24), and skin rash was documented as the most common reason for treatment discontinuation (7).

In the TITAN study, patients with mHSPC who received apalutamide in the Japanese subgroup population had relatively inferior primary efficacy outcomes than the overall population (25). These results suggested that SGARA may also have distinct efficacy or

---

**FIGURE 3** | Network meta-analysis forest plot of adverse events of treatments compared with darolutamide. (A) Any adverse events. (B) Adverse events of grade 3 or higher. (C) Serious adverse events.
### FIGURE 4
Subgroup analysis of overall survival.

| Study or Subgroup | log[Hazard Ratio] | SE | Weight | IV, Random, 95% CI | Hazard Ratio | IV, Random, 95% CI |
|-------------------|------------------|----|--------|-----------------|-------------|------------------|
| **1.4.1 PSADT > 6m** |                  |    |        |                 |             |                  |
| Fizazi 2020       | -0.594           | 0.237 | 28.8%  | 0.55 [0.35, 0.88] |             |                  |
| Smith 2020        | -0.431           | 0.202 | 37.1%  | 0.65 [0.44, 0.97] |             |                  |
| Sternberg 2020    | -0.105           | 0.213 | 34.1%  | 0.90 [0.59, 1.37] |             |                  |
| **Subtotal (95% CI)** | **100.0%**       |    |        | 0.69 [0.53, 0.91] |             |                  |
| Heterogeneity: Tau² = 0.01; Chi² = 2.53, df = 2 (P = 0.28); I² = 21% | | | | | |
| Test for overall effect: Z = 2.61 (P = 0.009) | | | | | |
| **1.4.2 PSADT < 6m** |                  |    |        |                 |             |                  |
| Fizazi 2020       | -0.308           | 0.153 | 21.1%  | 0.73 [0.54, 0.99] |             |                  |
| Smith 2020        | -0.174           | 0.115 | 37.3%  | 0.84 [0.67, 1.05] |             |                  |
| Sternberg 2020    | -0.371           | 0.109 | 41.6%  | 0.69 [0.56, 0.85] |             |                  |
| **Subtotal (95% CI)** | **100.0%**       |    |        | 0.75 [0.66, 0.86] |             |                  |
| Heterogeneity: Tau² = 0.00; Chi² = 1.58, df = 2 (P = 0.45); I² = 0% | | | | | |
| Test for overall effect: Z = 4.04 (P < 0.0001) | | | | | |
| **1.4.3 Osteoplast–target therapy: Y** |                  |    |        |                 |             |                  |
| Fizazi 2020       | -1.259           | 0.616 | 21.2%  | 0.28 [0.08, 0.95] |             |                  |
| Smith 2020        | -0.58            | 0.301 | 39.6%  | 0.56 [0.31, 1.01] |             |                  |
| Sternberg 2020    | 0.157            | 0.307 | 39.2%  | 1.17 [0.64, 2.14] |             |                  |
| **Subtotal (95% CI)** | **100.0%**       |    |        | 0.65 [0.32, 1.32] |             |                  |
| Heterogeneity: Tau² = 0.24; Chi² = 5.48, df = 2 (P = 0.06); I² = 64% | | | | | |
| Test for overall effect: Z = 1.20 (P = 0.23) | | | | | |
| **1.4.4 Osteoplast–target therapy: N** |                  |    |        |                 |             |                  |
| Fizazi 2020       | -0.337           | 0.131 | 23.5%  | 0.71 [0.55, 0.92] |             |                  |
| Smith 2020        | -0.198           | 0.107 | 35.3%  | 0.82 [0.67, 1.01] |             |                  |
| Sternberg 2020    | -0.371           | 0.099 | 41.2%  | 0.69 [0.57, 0.84] |             |                  |
| **Subtotal (95% CI)** | **100.0%**       |    |        | 0.74 [0.65, 0.84] |             |                  |
| Heterogeneity: Tau² = 0.00; Chi² = 1.50, df = 2 (P = 0.47); I² = 0% | | | | | |
| Test for overall effect: Z = 4.75 (P < 0.00001) | | | | | |
| **1.4.5 ECOG PS: 0** |                  |    |        |                 |             |                  |
| Fizazi 2020       | -0.472           | 0.169 | 19.2%  | 0.62 [0.45, 0.87] |             |                  |
| Smith 2020        | -0.301           | 0.123 | 36.3%  | 0.74 [0.58, 0.94] |             |                  |
| Sternberg 2020    | -0.342           | 0.111 | 44.5%  | 0.71 [0.57, 0.88] |             |                  |
| **Subtotal (95% CI)** | **100.0%**       |    |        | 0.70 [0.61, 0.81] |             |                  |
| Heterogeneity: Tau² = 0.00; Chi² = 0.68, df = 2 (P = 0.71); I² = 0% | | | | | |
| Test for overall effect: Z = 4.75 (P < 0.00001) | | | | | |
| **1.4.6 ECOG PS: 1** |                  |    |        |                 |             |                  |
| Fizazi 2020       | -0.304           | 0.195 | 31.3%  | 0.74 [0.50, 1.08] |             |                  |
| Smith 2020        | -0.117           | 0.183 | 35.5%  | 0.89 [0.62, 1.27] |             |                  |
| Sternberg 2020    | -0.274           | 0.189 | 33.3%  | 0.76 [0.52, 1.10] |             |                  |
| **Subtotal (95% CI)** | **100.0%**       |    |        | 0.80 [0.64, 0.99] |             |                  |
| Heterogeneity: Tau² = 0.00; Chi² = 0.58, df = 2 (P = 0.75); I² = 0% | | | | | |
| Test for overall effect: Z = 2.09 (P = 0.04) | | | | | |
| **1.4.7 Region: North America** |                  |    |        |                 |             |                  |
| Fizazi 2020       | -1.478           | 0.528 | 19.1%  | 0.23 [0.08, 0.64] |             |                  |
| Smith 2020        | -0.073           | 0.163 | 44.1%  | 0.93 [0.68, 1.28] |             |                  |
| Sternberg 2020    | -0.274           | 0.255 | 36.8%  | 0.76 [0.46, 1.25] |             |                  |
| **Subtotal (95% CI)** | **100.0%**       |    |        | 0.66 [0.37, 1.17] |             |                  |
| Heterogeneity: Tau² = 0.17; Chi² = 6.53, df = 2 (P = 0.04); I² = 69% | | | | | |
| Test for overall effect: Z = 1.42 (P = 0.15) | | | | | |

Test for subgroup differences: Chi² = 1.45, df = 6 (P = 0.96), I² = 0%
AE outcomes in the Asian population from the overall population. More studies are expected to investigate the outcomes of SGARAs in Asian population, especially studies in Chinese population.

This is a valuable network meta-analysis using the latest long-term outcomes of OS and AEs to compare the efficacy and safety of SGARAs in patients with high-risk nmCRPC, which may provide valuable information to both urologists and nmCRPC patients. But there were still some limitations that should be noticed. First, though NMA was conducted to outline a rough picture of indirect comparison of efficacy and safety among SGARAs, direct head-to-head comparisons among SGARAs were still lacking, to combine with indirect outcomes for a more convincing pooled outcome; heterogeneity also failed to be evaluated through NMA. Second, subgroup analysis of OS was failed to be performed in many subgroups due to lack of data and different cutoff levels across the included studies, so further exploration of overall survival in different subgroup populations cannot be carried out. Subgroup classification in studies needs to be standardized and unified in the future. In addition, patients’ baseline characteristics may have significant difference among included studies, which may affect the comparability of outcomes from the different studies. For example, patients with previous seizure or conditions predisposing to seizure were excluded in PROSPER and SPARTAN trials (6, 7), while included in ARAMIS trial (5). And N1 patients were included in ARAMIS and SPARTAN trials, while PROSPER study only included N0 patients.

CONCLUSION

SGARAs combined with ADT significantly improved OS when compared with ADT alone in nmCRPC patients. Darolutamide may provide potentially best OS, and at the same time, it appeared to have the most favorable safety profile among the included SGARAs in high-risk nmCRPC patients. Direct head-to-head comparison among SGARAs is required to confirm these findings.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

REFERENCES

1. Mateo J, Fizazi K, Gillessen S, Heidenreich A, Perez–Lopez R, Oyen WJG, et al. Managing Nonmetastatic Castration-Resistant Prostate Cancer. Eur Urol (2019) 75(2):285–93. doi: 10.1016/j.euro.2018.07.035

FUNDING

This work was supported by the National key research and development program of China (Grant No. 2017YFC0908003, 2017YFC010900), National Natural Science Foundation of China(Grant No. 82072826) and Special Project of “Group Medical Assistance Project” of Tibet Autonomous Region Health Committee (Grant No. XZ2019ZR-ZY16(Z)).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.733202/full#supplementary-material

Supplementary Figure 1 | Flowchart of studies selection process.
Supplementary Figure 2 | Risk of bias assessment of included studies.
Supplementary Figure 3 | Network meta-analysis OS p-score plot of treatments. A higher p-score represent a higher possibility to have better OS.
Supplementary Figure 4 | Network meta-analysis forest plot of overall survival of treatments compared with darolutamide.
Supplementary Figure 5 | Network meta-analysis forest plot of the use of subsequent antineoplastic therapy, other treatments compared with darolutamide.
Supplementary Figure 6 | Surface under the cumulative ranking (SUCRA) plot of the treatments included. A darker color is proportional to a less use of subsequent antineoplastic therapy.
Supplementary Figure 7 | Network meta-analysis forest plot of subgroup patients who received osteoplast-targeting therapy, other treatments compared with darolutamide.
Supplementary Figure 8 | Network meta-analysis forest plot of subgroup patients in the region of North America, other treatments compared with darolutamide.

Supplement Material 1 | "(non metastast)*[Title/Abstract] OR (‘non’[All Fields] AND "metastast"[AI[Fields] OR "non metastast"[Title/Abstract] OR local*[Title/Abstract] AND ‘randomized controlled trial’[Publication Type]) AND (‘prostatic neoplasms, castration resistant’[Drug/Chemical]) OR (‘androgen’[Title/Abstract] OR ‘castration’[Title/Abstract] OR ‘hormone’[Title/Abstract] AND ‘(independent’[Title/Abstract] OR ‘insensitive’[Title/Abstract] OR ‘resistant’[Title/Abstract] OR ‘refractory’[Title/Abstract] AND ‘prostate’[Title/Abstract] AND ‘cancer’[Title/Abstract] OR ‘neoplasm’[Title/Abstract] OR ‘tumor’[Title/Abstract] OR ‘(abirateron’[Title/Abstract] OR ‘apalutamide’[Title/Abstract] OR ‘darolutamide’[Title/Abstract] OR ‘enzalutamide’[Title/Abstract] OR ‘(androgen receptor antagonists’[Pharmacological Action] OR ‘(androgen receptor antagonists’[MeSH Terms] OR (‘androgen’[AI[Fields] AND ‘resistant’[AI[Fields] OR ‘(antineoplastic agents’[Pharmacological Action] OR ‘(antineoplastic agents’[MeSH Terms] OR ‘(antineoplastic’[AI[Fields] AND ‘agents’[AI[Fields] OR ‘(antineoplastic’[AI[Fields] AND ‘(antineoplastic agents’[MeSH Terms] OR ‘(antineoplastic’[AI[Fields] AND ‘agents’[AI[Fields] OR ‘(antineoplastic’[AI[Fields] AND ‘(randomized controlled trial’[Publication Type])

2. Hess-Busch Y, Hadashick B, Hess J. mCrPCPC Overview of Management Options. World J Urol (2021) 39(2):349–56. doi: 10.1007/s00345-019-02997-z
3. Horwich A, Hugoson J, de Reijke T, Wiegel T, Fizazi K, Kataja V, et al. Prostate Cancer: ESMO Consensus Conference Guidelines 2012. Ann Oncol (2013) 24(5):1141–62. doi: 10.1093/annonc/mds6624
Novel Hormonal Therapies for nmCRPC

Mohler J, Bahnson RR, Boston B, Busby JE, D’Amico A, Eastham JA, et al. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. J Natl Compr Canc Netw (2010) 8(2):161–200. doi: 10.6004/jnccn.2010.0052

Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med (2019) 380(13):1235–46. doi: 10.1056/NEJMoa1815671

Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in Men With Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med (2018) 378(26):2465–74. doi: 10.1056/NEJMoa1805366

Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide Treatment and Metastasis-Free Survival in Prostate Cancer. N Engl J Med (2018) 378(15):1408–18. doi: 10.1056/NEJMoa1715546

Sternberg CN, Fizazi K, Saad F, Shore ND, de Giorgi U, Penso DF, et al. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med (2020) 382(23):2197–206. doi: 10.1056/NEJMoa2003892

Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide and Overall Survival in Prostate Cancer. Eur Urol (2020) 79(1):150–8. doi: 10.1016/j.euro.2020.08.011

Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival With Darolutamide. N Engl J Med (2020) 383(11):1040–9. doi: 10.1056/NEJMoa2003142

Moher D, Liberati A, Tetzlaff J, Altman DG, Grp P. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. J Clin Epidemiol (2009) 62(10):1006–12. doi: 10.1016/j.jclinepi.2009.06.005

Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-Analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med (2015) 162(11):777–84. doi: 10.7326/M14-2385

Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s Tool for Assessing Risk of Bias in Randomised Trials. BMJ Brit Med J (2011) 343:d5928. doi: 10.1136/bmj.d5928

Wood BS, Hawkins N, Scott DA. Network Meta-Analysis on the Log-Hazard Scale, Combining Count and Hazard Ratio Statistics Accounting for Multi-Arm Trials: A Tutorial. BMC Med Res Methodol (2010) 10:54. doi: 10.1186/1471-2288-10-54

Loriot Y, Supiot S, Beauval JB, Schlummann F, Pasticier G, Sargos P, et al. Management of non-Metastatic Castrate-Resistant Prostate Cancer: A Systematic Review. Cancer Treat Rev (2018) 70:223–31. doi: 10.1016/j.ctrv.2018.09.006

Hird AE, Magee DE, Bhindi B, Ye XY, Chandrasekar T, Goldberg H, et al. A Systematic Review and Network Meta-Analysis of Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer (2020) 18(5):343–50. doi: 10.1016/j.clgc.2020.02.005

Kumar J, Jazayeri SB, Gautam S, Norez D, Alam MU, Tanneru K, et al. Comparative Efficacy of Apalutamide Darolutamide and Enzalutamide for Treatment of non-Metastatic Castrate-Resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis. Urol Oncol (2020) 38(11):826–34. doi: 10.1016/j.urolonc.2020.03.022

Mori K, Mostafaei H, Pradere B, Moliagh RS, Quhal F, Laukhina E, et al. Apalutamide, Enzalutamide, and Darolutamide for non-Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis. Int J Clin Oncol (2020) 25(11):1892–900. doi: 10.1007/s10147-020-01777-9

Liu Z, Zhang T, Ma Z, Zheng S, Chen J, Wu Z, et al. Systematic Management for Nonmetastatic Castration-Resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis. Am J Clin Oncol (2020) 43(4):288–97. doi: 10.1097/COC.0000000000001660

Zurth C, Sandmann S, Trummel D, Seidel D, Gieschen H. Blood-Brain Barrier Penetration of [14C]Darolutamide Compared With [14C]Enzalutamide in Rats Using Whole-Body Autoradiography. J Clin Oncol (2018) 36(6). doi: 10.1200/JCO.2018.36.6_suppl.345

Borgmann H, Lallouz N, Ozistanbullu D, Beraldi E, Paul N, Dalal K, et al. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-Resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201). Eur Urol (2018) 73(1):4–8. doi: 10.1016/j.eururo.2017.08.012

Moilanen AM, Rikonen R, Oksala R, Ravanti L, Aho E, Wohlforth G, et al. Discovery of ODM-201, a New-Generation Androgen Receptor Inhibitor Targeting Resistance Mechanisms to Androgen Signaling-Directed Prostate Cancer Therapies. Sci Rep (2015) 5:12007. doi: 10.1038/srep12007

Uemura H, Matsushima H, Kobayashi K, Mizusawa H, Nishimatsu H, Fizazi K, et al. Efficacy and Safety of Darolutamide in Japanese Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Group Analysis of the Phase III ARAMIS Trial. Int J Clin Oncol (2021) 26(3):578–90. doi: 10.1007/s10147-021-01824-5

Uemura H, Sato T, Tsuura H, Arai G, Imanaka K, Shibayama K, et al. Efficacy and Safety of Apalutamide in Japanese Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Subgroup Analysis of a Randomized, Double-Blind, Placebo-Controlled, Phase-3 Study. Prostate Int (2020) 8(4):190–7. doi: 10.1016/j.pri.2020.05.002

Uemura H, Arai G, Uemura H, Suzuki H, Iijima K, Nishimura K, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer in the Japanese Population: A Subgroup Analysis of the Randomized, Double-Blind, Placebo-Controlled Phase 3 TITAN Study. Int J Urol (2021) 28(3):280–7. doi: 10.1111/iju.14447

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Mulati, Fan, Yu, Zhang and He. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.